PF-03635659 is a potent, very long dissociative half-life (slow off-rate, >1440 min) muscarinic M3 antagonist. Spirometry data from healthy volunteers in phase I clinical studies illustrate that PF-03635659 provides efficacious 24 h bronchodilation from a single inhaled dose, thus confirming the suitability of PF-03635659 as a novel once-daily inhaled muscarinic M3 receptor antagonist for the treatment of chronic obstructive pulmonary disease (COPD). Safety (tachycardia) and toleration (dry mouth) data from the multidose phase I studies indicate an adverse event profile that is at least noninferior to tiotropium bromide. PF-03635659 had been in phase II clinical trial for the treatment of chronic obstructive pulmonary disease.

Safotibant (previously known as LF22-0542) was developed as an antagonist at bradykinin B1 receptor for the topical treatment of diabetic macular edema. This drug participated in phase II clinical trials in Australia, in Belgium and in the Czech Republic. However, further, development was discontinued.

Dimepranol is an immunomodulator and antiviral agent. As a mixture ingredient dimepranol was used for the treatment of recurrent local herpes simplex virus infections but results have been disappointing. As a component of inosine pranobex, dimepranol was licensed for the treatment of cell-mediated immune deficiencies associated with viral infections. In particular, for the management of: Mucocutaneous infections due to herpes simplex virus (type 1 and/or type 2); Genital warts as adjunctive therapy to podophyllin or carbon dioxide laser; Subacute sclerosing panencephalitis. Dimepranol in treatment regimens with antibiotics and inosin didn’t show any effect on PFAPA syndrome management.

Chlorpyrifos-methyl is a broad-spectrum organophosphorous insecticide and potential toxic pollutant widely used in agriculture and effective against a wide range of insect pests in commercial importance crops. Chlorpyrifos-methyl have endocrine disruption activity, especially anti-androgenic effects and Chlorpyrifos-methyl administration leads to hepatotoxicity and neurotoxicity in mammals. The fish exposed to chlorpyrifos-methyl exhibited behavioral changes in the form of neurotoxin toxicity: less general activity than control group, loss of equilibrium, erratic swimming and staying motionless at a certain location

Lapachone (aka beta-Lapachone) is an ortho naphthoquinone, originally isolated from a tree whose extract has been used medicinally for centuries. It has garnered interest as a potential therapeutic or lead compound against a number of disease conditions including cancers, and blindness due to retinopathy of prematurity. It is lethal to a number of cancer cell types at micromolar concentrations, and it is capable of enhancing the efficacy of radiation therapies against cultured cells. A number of clinical trials have been conducted.

Licofelone (ML 3000) is a pyrrolizine derivative originally discovered by Merckle GmbH and developed by EuroAllaince with a unique pharmacological profile, which comprises optimal gastrointestinal tolerability and high analgesic and anti-inflammatory activity. These effects are due to balanced and selective inhibition of both cyclo-oxygenase and 5-lipoxygenase. Inhibition of 5-lipoxygenase may reduce the gastrointestinal toxicity associated with other non steroidal anti-inflammatory drugs, which only inhibit cyclooxygenase. Licofelone also has antipyretic and antiaggregatory properties. Clinical and preclinical trials were also undertaken for osteoarthritis, rheumatoid arthritis, asthma, pain and inflammation. However, development for these indications appear to have been discontinued.

BIPHENYL DIMETHYL DICARBOXYLATE (BDD) under the brand name Nissel is used in the South Corea for the treatment of chronic hepatitis followed by an increase in serum alanine aminotransferase levels continuously. This compound also participated in clinical trials phase III in the patients with chronic liver disease. In addition, the drug was studied in phase III clinical trials after laparoscopic cholecystectomy. The use of BDD in patients with cholecystitis was expected to inhibit elevated liver enzyme levels and to maintain liver function.